Прогноз погоды

People

John Smith

John Smith, 47

Joined: 28 January 2014

Interests: No data

Jonnathan Coleman

Jonnathan Coleman, 31

Joined: 18 June 2014

About myself: You may say I'm a dreamer

Interests: Snowboarding, Cycling, Beer

Andrey II

Andrey II, 40

Joined: 08 January 2014

Interests: No data

David

David

Joined: 05 August 2014

Interests: No data

David Markham

David Markham, 64

Joined: 13 November 2014

Interests: No data

Michelle Li

Michelle Li, 40

Joined: 13 August 2014

Interests: No data

Max Almenas

Max Almenas, 52

Joined: 10 August 2014

Interests: No data

29Jan

29Jan, 30

Joined: 29 January 2014

Interests: No data

s82 s82

s82 s82, 25

Joined: 16 April 2014

Interests: No data

Wicca

Wicca, 35

Joined: 18 June 2014

Interests: No data

Phebe Paul

Phebe Paul, 25

Joined: 08 September 2014

Interests: No data

Артем 007

Артем 007, 40

Joined: 29 January 2014

About myself: Таки да!

Interests: Норвегия и Исландия

jomo

jomo

Joined: 27 November 2018

Interests: No data

Alexey Geno

Alexey Geno, 7

Joined: 25 June 2015

About myself: Хай

Interests: Интерес1daasdfasf

Verg Matthews

Verg Matthews, 67

Joined: 25 June 2015

Interests: No data



Main article: Matrix Partners China

All topics: 7

Alibaba-backed parenting site Babytree starts taking orders for downsized IPO

17:12 | 27 November

A lot of Chinese millennials may be delaying or opting out of childbearing, but those who have committed to parenting often go all out to ensure their children grow up healthy and do well in school.

One company capitalizing on China’s booming mother and infant industry – which is expected to double in market valuation between 2015 and 2018 to top $520 billion, according to consulting firm Roland Berger – is Babytree. The Beijing-based firm started trading on the Hong Kong Stock Exchange on Tuesday.

Founded in 2007, Babytree operates an online platform for parents to exchange know-how, shop for baby goods, and purchase early education services.

The firm debuted at HK$6.91, or $0.88, compared to its IPO price of HK$6.80. That values Babytree at HK$11.5 billion, or $1.47 billion, well below its May valuation of $2.19 billion after it inked a strategic investment from Alibaba that saw the partners collaborating on multiple fronts, including ecommerce, advertising, and paid content.

Last week, Babytree slashed its IPO by 70 percent to $282 million amid waning investor interest in Hong Kong.

Babytree, in which Alibaba owns a 9.9 percent stake, was started in 2007 by venture capitalist Shao Yibo – who founded Matrix Partners’ China subsidiary and EachNet, which Ebay bought out in 2003 to take on Alibaba’s Taobao – and former Yahoo and Google executive Wang Huainan.

Babytree’s other major investor is Chinese conglomerate and investment firm Fosun International, which has also backed its smaller competitor Qinbaboao, a social media service for young parents to share photos and knowledge.

The parenting portal reached an average of 175 million monthly active users between July and September, according to its IPO prospectus. Qinbaobao claimed to have more than 70 million registered users when it raised hundreds of millions of RMB in a series C funding round in October.

Babytree generates most of its revenues from advertising fees and ecommerce transactions, but Wang the co-founder said recently that paid content is one of the company’s fastest-growing segment. The parenting site posted revenues of 408 million yuan, or $58.6 million, in the first half of 2018, up 12 percent from the same period a year ago. Its adjusted profit increased by 30 percent to 122 million yuan, or $17.6 million, during the same period.

 


0

China is funding the future of American biotech

20:15 | 20 October

Silicon Valley is in the midst of a health craze, and it is being driven by “Eastern” medicine.

It’s been a record year for US medical investing, but investors in Beijing and Shanghai are now increasingly leading the largest deals for US life science and biotech companies. In fact, Chinese venture firms have invested more this year into life science and biotech in the US than they have back home, providing financing for over 300 US-based companies, per Pitchbook. That’s the story at Viela Bio, a Maryland-based company exploring treatments for inflammation and autoimmune diseases, which raised a $250 million Series A led by three Chinese firms.

Chinese capital’s newfound appetite also flows into the mainland. Business is booming for Chinese medical startups, who are also seeing the strongest year of venture investment ever, with over one hundred companies receiving $4 billion in investment.

As Chinese investors continue to shift their strategies towards life science and biotech, China is emphatically positioning itself to be a leader in medical investing with a growing influence on the world’s future major health institutions.

Chinese VCs seek healthy returns

We like to talk about things we can interact with or be entertained by. And so as nine-figure checks flow in and out of China with stunning regularity, we fixate on the internet giants, the gaming leaders or the latest media platform backed by Tencent or Alibaba.

However, if we follow the money, it’s clear that the top venture firms in China have actually been turning their focus towards the country’s deficient health system.

A clear leader in China’s strategy shift has been Sequoia Capital China, one of the country’s most heralded venture firms tied to multiple billion-dollar IPOs just this year.

Historically, Sequoia didn’t have much interest in the medical sector.  Health was one of the firm’s smallest investment categories, and it participated in only three health-related deals from 2015-16, making up just 4% of its total investing activity. 

Recently, however, life sciences have piqued Sequoia’s fascination, confirms a spokesperson with the firm.  Sequoia dove into six health-related deals in 2017 and has already participated in 14 in 2018 so far.  The firm now sits among the most active health investors in China and the medical sector has become its second biggest investment area, with life science and biotech companies accounting for nearly 30% of its investing activity in recent years.

Health-related investment data for 2015-18 compiled from Pitchbook, Crunchbase, and SEC Edgar

There’s no shortage of areas in need of transformation within Chinese medical care, and a wide range of strategies are being employed by China’s VCs. While some investors hope to address influenza, others are focused on innovative treatments for hypertension, diabetes and other chronic diseases.

For instance, according to the Chinese Journal of Cancer, in 2015, 36% of world’s lung cancer diagnoses came from China, yet the country’s cancer survival rate was 17% below the global average. Sequoia has set its sights on tackling China’s high rate of cancer and its low survival rate, with roughly 70% of its deals in the past two years focusing on cancer detection and treatment.

That is driven in part by investments like the firm’s $90 million Series A investment into Shanghai-based JW Therapeutics, a company developing innovative immunotherapy cancer treatments. The company is a quintessential example of how Chinese VCs are building the country’s next set of health startups using their international footprints and learnings from across the globe.

Founded as a joint-venture offshoot between US-based Juno Therapeutics and China’s WuXi AppTec, JW benefits from Juno’s experience as a top developer of cancer immunotherapy drugs, as well as WuXi’s expertise as one of the world’s leading contract research organizations, focusing on all aspects of the drug R&D and development cycle.

Specifically, JW is focused on the next-generation of cell-based immunotherapy cancer treatments using chimeric antigen receptor T-cell (CAR-T) technologies. (Yeah…I know…) For the WebMD warriors and the rest of us with a medical background that stopped at tenth-grade chemistry, CAR-T essentially looks to attack cancer cells by utilizing the body’s own immune system.

Past waves of biotech startups often focused on other immunologic treatments that used genetically-modified antibodies created in animals.  The antibodies would effectively act as “police,” identifying and attaching to “bad guy” targets in order to turn off or quiet down malignant cells.  CAR-T looks instead to modify the body’s native immune cells to attack and kill the bad guys directly.

Chinese VCs are investing in a wide range of innovative life science and biotech startups. (Photo by Eugeneonline via Getty Images)

The international and interdisciplinary pedigree of China’s new medical leaders not only applies to the organizations themselves but also to those running the show.

At the helm of JW sits James Li.  In a past life, the co-founder and CEO held stints as an executive heading up operations in China for the world’s biggest biopharmaceutical companies including Amgen and Merck.  Li was also once a partner at the Silicon Valley brand-name investor, Kleiner Perkins.

JW embodies the benefits that can come from importing insights and expertise, a practice that will come to define the companies leading the medical future as the country’s smartest capital increasingly finds its way overseas.

GV and Founders Fund look to keep the Valley competitive

Despite heavy investment by China’s leading VCs, Silicon Valley is doubling down in the US health sector.  (AFP PHOTO / POOL / JASON LEE)

Innovation in medicine transcends borders. Sickness and death are unfortunately universal, and groundbreaking discoveries in one country can save lives in the rest.

The boom in China’s life science industry has left valuations lofty and cross-border investment and import regulations in China have improved.

As such, Chinese venture firms are now increasingly searching for innovation abroad, looking to capitalize on expanding opportunities in the more mature US medical industry that can offer innovative technologies and advanced processes that can be brought back to the East.

In April, Qiming Venture Partners, another Chinese venture titan, closed a $120 million fund focused on early-stage US healthcare. Qiming has been ramping up its participation in the medical space, investing in 24 companies over the 2017-18 period.

New firms diving into the space hasn’t frightened the Bay Area’s notable investors, who have doubled down in the US medical space alongside their Chinese counterparts.

Partner directories for America’s most influential firms are increasingly populated with former doctors and medically-versed VCs who can find the best medical startups and have a growing influence on the flow of venture dollars in the US.

At the top of the list is Krishna Yeshwant, the GV (formerly Google Ventures) general partner leading the firm’s aggressive push into the medical industry.

Krishna Yeshwant (GV) at TechCrunch Disrupt NY 2017

A doctor by trade, Yeshwant’s interest runs the gamut of the medical spectrum, leading investments focusing on anything from real-time patient care insights to antibody and therapeutic technologies for cancer and neurodegenerative disorders.

Per data from Pitchbook and Crunchbase, Krishna has been GV’s most active partner over the past two years, participating in deals that total over a billion dollars in aggregate funding.

Backed by the efforts of Yeshwant and select others, the medical industry has become one of the most prominent investment areas for Google’s venture capital arm, driving roughly 30% of its investments in 2017 compared to just under 15% in 2015.

GV’s affinity for medical-investing has found renewed life, but life science is also part of the firm’s DNA.  Like many brand-name Valley investors, GV founder Bill Maris has long held a passion for the health startups.  After leaving GV in 2016, Maris launched his own fund, Section 32, focused specifically on biotech, healthcare and life sciences. 

In the same vein, life science and health investing has been part of the lifeblood for some major US funds including Founders Fund, which has consistently dedicated over 25% of its deployed capital to the space since at least 2015.

The tides may be changing, however, as the recent expansion of oversight for the Committee on Foreign Investment in the United States (CFIUS) may severely impact the flow of Chinese capital into areas of the US health sector. 

Under its extended purview, CFIUS will review – and possibly block – any investment or transaction involving a foreign entity related to the production, design or testing of technology that falls under a list of 27 critical industries, including biotech research and development.

The true implications of the expanded rules will depend on how aggressively and how often CFIUS exercises its power.  But a lengthy review process and the threat of regulatory blocks may significantly increase the burden on Chinese investors, effectively shutting off the Chinese money spigot.

Regardless of CFIUS, while China’s active presence in the US health markets hasn’t deterred Valley mainstays, with a severely broken health system and an improved investment environment backed by government support, China’s commitment to medical innovation is only getting stronger.

VCs target a disastrous health system

Deficiencies in China’s health sector has historically led to troublesome outcomes.  Now the government is jump-starting investment through supportive policy. (Photo by Alexander Tessmer / EyeEm via Getty Images)

They say successful startups identify real problems that need solving. Marred with inefficiencies, poor results, and compounding consumer frustration, China’s health industry has many

Outside of a wealthy few, citizens are forced to make often lengthy treks to overcrowded and understaffed hospitals in urban centers.  Reception areas exist only in concept, as any open space is quickly filled by hordes of the concerned, sick, and fearful settling in for wait times that can last multiple days. 

If and when patients are finally seen, they are frequently met by overworked or inexperienced medical staff, rushing to get people in and out in hopes of servicing the endless line behind them. 

Historically, when patients were diagnosed, treatment options were limited and ineffective, as import laws and affordability issues made many globally approved drugs unavailable.

As one would assume, poor detection and treatment have led to problematic outcomes. Heart disease, stroke, diabetes and chronic lung disease accounts for 80% of deaths in China, according to a recent report from the World Bank

Recurring issues of misconduct, deception and dishonesty have amplified the population’s mounting frustration.

After past cases of widespread sickness caused by improperly handled vaccinations, China’s vaccine crisis reached a breaking point earlier this year.  It was revealed that 250,000 children had been given defective and fallacious rabies vaccinations, a fact that inspectors had discovered months prior and swept under the rug.

Fracturing public trust around medical treatment has serious, potentially destabilizing effects. And with deficiencies permeating nearly all aspects of China’s health and medical infrastructure, there is a gaping set of opportunities for disruptive change.

In response to these issues, China’s government placed more emphasis on the search for medical innovation by rolling out policies that improve the chances of success for health startups, while reducing costs and risk for investors.

Billions of public investment flooded into the life science sector, and easier approval processes for patents, research grants, and generic drugs, suddenly made the prospect of building a life science or biotech company in China less daunting. 

For Chinese venture capitalists, on top of financial incentives and a higher-growth local medical sector, loosening of drug import laws opened up opportunities to improve China’s medical system through innovation abroad.

Liquidity has also improved due to swelling global interest in healthcare. Plus, the Hong Kong Stock Exchange recently announced changes to allow the listing of pre-revenue biotech companies.

The changes implemented across China’s major institutions have effectively provided Chinese health investors with a much broader opportunity set, faster growth companies, faster liquidity, and increased certainty, all at lower cost.

However, while the structural and regulatory changes in China’s healthcare system has led to more medical startups with more growth, it hasn’t necessarily driven quality.

US and Western investors haven’t taken the same cross-border approach as their peers in Beijing. From talking with those in the industry, the laxity of the Chinese system, and others, have made many US investors weary of investing in life science companies overseas.

And with the Valley similarly stepping up its focus on startups that sprout from the strong American university system, bubbling valuations have started to raise concern.

But with China dedicating more and more billions across the globe, the country is determined to patch the massive holes in its medical system and establish itself as the next leader in international health innovation.

 


0

Sino-U.S. investment firms are targeting over $4 billion for new funds launched this year

20:50 | 17 August

As limited partners increasingly demand greater exposure to emerging market opportunities, venture capital firms with a focus on Asia are bulking up their funds and chasing deals in an increasingly competitive race to own stakes in the next generation of local startups with global aspirations.

Over the last year, firms including DCM Ventures, GGV CapitalMatrix Partners China, and Qiming Venture Partners have all significantly increased the targets for their new funds. If each firm hits their targets, there’s roughly $4.4 billion in new capital that could be flooding into an already scorching market for investment into Chinese startups, according to SEC filings.

The largest of these new funds, by far, is GGV Capital, which has registered a new $1.8 billion fund with the Securities and Exchange Commission. Qiming Ventures has targeted $900 million for its latest fund, while DCM Ventures and Matrix Partners China are each looking for $750 million for their own new investment vehicles, according to securities filings.

Managing partners at the firms did not respond to a request for comment.

These four firms are among the last standing from the initial flood of U.S.-based venture capital firms that poured into Asia (and China specifically) in the first decade of the new millennium.

While marquee names like Kleiner Perkins, DFJ and others foundered in China, these four firms (along with global venture capital juggernauts like Sequoia Capital and NEA) put down deep roots and notched notable wins with investments in startups like Didi-Chuching, Kuaidi, Meituan-Dianping, Xiaomi, and many many more.

In part, these massive new funds are simply a response to the new world that venture investors find themselves in thanks to the massive amounts of capital raised by SoftBank with its $100 billion Vision Fund, or Sequoia with its $9 billion new investment vehicle.

Firms are also under pressure to raise more capital from limited partners, who want to reduce their exposure and consolidate their own investments around venture firms with track records of success and the ability to deploy capital into larger checks.

Couple those facts with the (still) low cost of capital given where interest rates are, and the sustained growth of technology companies across emerging market geographies, and you have a more willing pool of investors that want to commit more capital to emerging technology ecosystems (this is happening in Latin America too).

But there are also some contours of China’s competitive environment that are pushing these venture capital firms to raise increasingly larger funds.

One is the sheer size of the opportunity that exists for new technology companies in China. As the WeChat messaging service increasingly evolves into a new operating system, there are opportunities to scale quickly with larger infusions of capital to capture the market.

Like their peers in the U.S., Chinese companies are also delaying their public offerings and spending more time to build a better outcome with their IPOs. That’s putting pressure on earlier stage investors to raise capital so they don’t get crowded out in those later stage rounds.

Chinese entrepreneurs are also often putting in their own money to finance companies at the earliest stages, which means startups are more mature when they’re seeking their first round. It’s this phenomenon which leads to the $100 million Series A and B rounds that crop up in the Chinese market more regularly than in the U.S.

 


0

New unicorn Klook raises $200M to expand its travel activities platform worldwide

14:57 | 7 August

Klook, a Hong Kong-based startup developing a travel activities platform, has pulled in $200 million in new capital to fuel a major expansion into the U.S. and Europe. A spokesperson confirmed to TechCrunch that the round values the company at more than $1 billion, although the company didn’t provide an exact figure.

Klook sets out to make booking travel activities as easy as arranging flights and hotels. That could mean visits to adventure parks, scuba diving, more localized tours or basics such as train travel, food or airport transfers, all of which can be found, paid for and taken using Klook’s platform. The company claims to offer more than 50,000 activities and services from 5,000 partners in over 200 destinations across the world. The startup claims its platform is on track to gross $1 billion in bookings — which is not take home revenue — for this year.

That booking milestone is “not just a representation of how Klook has grown but also a representation of this space,” Klook co-founder and COO Eric Gnock Fah told TechCrunch in an interview. “A lot of people thought this was a very niche sector, but it is proving to be a very valuable industry [and] we’re glad to be the leader.”

There’s plenty of evidence to support that. Travel giant Booking.com jumped into the space via an acquisition earlier this year, while TripAdvisor and Airbnb are pushing the activities side of their businesses, too. More direct competition to Klook includes Taiwan’s KKday, which is aligned with Japanese travel giant H.I.S., U.S.-based Peek, Culture Trip, GetYourGuide and Headout.

Klook is the best-funded by some mile, having raised plenty of capital over the past year or so. It closed a $30 million Series B in March 2017 before adding a $60 million Series C the following October, and this new round takes it to nearly $300 million to date.

The new deal sees existing backers Sequoia China, Matrix Partners, and Goldman Sachs return to put in more capital. They’re joined by first-time investors China’s Boyu Capital, Technology Crossover Ventures (TCV) — which has backed Airbnb among others — and Israel’s OurCrowd, while an undisclosed Asian sovereign wealth fund and unnamed family offices also took part.

Four-year-old Klook has been in expansion mode for the past year, opening offices in London and Amsterdam and growing its headcount to 600 staff across 16 offices, predominantly in Asia. That’s up from 400 people across 13 offices last October.

Now, the company is eying the U.S. and a greater share of Europe. That’s not new, per se, Gnock Fah last year told us that North America was in the roadmap, but now the company has confirmed it’ll open a U.S. office before the end of 2018.

“It’s very likely to be East Coast — New York — where we’d start off in the U.S., but I believe we’ll scale up to have teams on the West Coast and probably mid-West, too,” Gnock Fah said. “We also continue to be expanding in Europe and look for the next location to set up more offices.”

This goal push is two-fold. It’s aimed at tapping into the increased demand for global travel from Asian tourists, and particularly those in China, whilst also bringing Western travelers to Asia where they can tap into Klook’s ecosystem of activities and services.

“This round is really gearing up to global expansion,” Gnock Fah said. “There’s still plenty of growth in Asia but now we will be really accelerating our growth into the U.S. and Europe. We’re really entering the global stage [and attracting an investor like] TCV is a testament to what we’re looking to achieve as a global player.”

The Klook COO also added that the company is seeking to open a new R&D center to supplement its existing tech hub that’s located in Shenzhen. The location for that new office is likely to be in Asia, he added, although its efforts will support the business worldwide.

 


0

Evolve Foundation launches a $100 million fund to find startups working to relieve human suffering

01:58 | 4 November

It seems there’s nothing but bad news out there lately, but here’s some good news — the nonprofit Evolve Foundation has raised $100 million for a new fund called the Conscious Accelerator to combat loneliness, purposelessness, fear and anger spreading throughout the world though technology.

Co-founder of Matrix Partners China Bo Shao will lead the fund and will be looking for entrepreneurs focusing on tech that can help people become more present and aware.

“I know a lot of very wealthy people and many are very anxious or depressed,” he told TechCrunch. A lot of this he contributes to the way we use technology, especially social media networks.

“It becomes this anxiety-inducing activity where I have to think about what’s the next post I should write to get most people to like me and comment and forward,” he said. “It seems that post has you trapped. Within 10 minutes, you are wondering how many people liked this, how many commented. It was so addicting.”

Teens are especially prone to this anxiety, he points out. It turns out it’s a real mental health condition known as Social Media Anxiety Disorder (SMAD).

“Social media is the new sugar or the new smoking of this generation,” Shao told TechCrunch.

He quit social media in September of 2013 but tells TechCrunch he’s been on a journey to find ways to improve his life and others for the last 10 years.

His new fund, as laid out in a recent Medium post announcement, seeks to maximize the social good, find solutions to the issues now facing us through technology, not just investing in something with good returns.

Shao plans to use his background as a prominent VC in a multi-billion-dollar firm to find those working on the type of technology to make us less anxious and more centered.

The Conscious Accelerator has already funded a meditation app called Inside Timer. It’s also going to launch a parenting app to help parents raise their children to be resilient in an often confusing world.

He’s also not opposed to funding projects like the one two UC Berkeley students put together to identify Russian and politically toxic Twitter bots — something Twitter has been criticized for not getting a handle on internally.

“The hope is we will attract entrepreneurs who are conscious,” Shao said.

Featured Image: Yann Cœuru/Flickr UNDER A CC BY 2.0 LICENSE

 


0

Klook raises $30M for its Asia-focused travel activity platform

16:47 | 2 March

Klook, a service for finding and booking travel activities, has closed a $30 million Series B funding round led by Sequoia China. Existing backers Matrix Partners and Welight Capital, a firm founded by former Tencent executives, also took part.

This new money takes Hong Kong-based Klook to $36.5 million from investors to date. Last October, it closed a $5 million Series A round led by Matrix. The startups’ advisors include the managing director of Agoda North Asia and the former vice chairman of the planning and financial department of the China National Tourism Administration.

Unlike regular travel startups, Klook doesn’t manage flights or hotels, it looks after the rest. It was founded in September 2014 as means to helping the increasing number of Asia-to-Asia travelers find activities and things to do while they are overseas. The company said that today its service includes details of 10,000 attractions, tours and general activities spanning 80 cities across Asia. It also gave out some pertinent business data for the first time. Last year, Klook helped users book five million trips — it clarified that the figure refers to two-way trips. We did ask about revenue and other financial details, but for now the company isn’t revealing those.

Operationally, Klook’s team has expanded to reach 200 staff while it has eight offices across Asia. Those local teams work with attraction and tour operators to source activities directly, thereby avoiding the hefty premium of booking through an agent to offer users a competitive price. It has also recently introduced services — such as local transfer options and WiFi device rental — that let users pick up travel essentials from inside the app. Klook co-founder and COO Eric Gnock Fah told TechCrunch in an interview that it would soon add options for restaurants, shopping and more.

“We’re moving towards being an in-destination service platform,” he said.

Beyond expanding into new verticals, which will presumably super charge monetization, Fah said Klook geographical extensions are planned. Klook plans to spend the year growing its reach to remaining major markets in Asia before looking to other parts of the world.

“Over the past few years we’ve basically nailed Asia’s supply chain,” he explained. “We will launch in Australia soon and then go full speed into Europe and North America.”

Those expansions are still designed to service Asia’s tourists — of which China is the dominant market — so it is activities that are suited to travelers from Asia. Initially, at least. But with the Tokyo Olympics on the horizon in 2020 — and the Winter Olympics taking place in Seoul next year — Fah anticipates that the company will need to cater to Western tourists visiting Asia sooner rather than later.

He’s also optimistic that the boom in inbound visitors to Asia will put Klook’s business in a good position.

“Some of the markets were are in are already reaching break even or profitable, so it’s just a case of getting into more markets,” he said. “Our IPO is always in the planning… the timeline we are looking at definitely before 2020. That’s mainly because of the Tokyo Olympics and next year’s Winter Olympics — you can imagine the travel trends over the next few years.”

A public listing might take place in the U.S. or Hong Kong, Fah offered, although those details are far from ironed out at this point. For one thing, he still anticipates that there “is likely to be at least one more round” of private funding before a move to the public markets. Still, with few startups exits in Asia — China aside — it is refreshing to hear a company committing its ambition to paper.

Featured Image: ipopba/iStock/Getty Images

 


0

Klook, An App For Booking Travel Activities Across Asia, Raises $5M

14:34 | 16 October

Klook, a Hong Kong-based company that sells travel activities across Asia, has announced a $5 million Series A round led by US-Sino investment fund Matrix Partners. China Growth Capital and Francis Leung, chairman of CVC Capital, also took part.

The company was founded in September 2014 with the idea of helping travelers and tourists find things to do across Asia. Klook raised a $1.5 million seed round in April, and co-founder Eric Gnock Fah told TechCrunch that this round was over-subscribed thanks to impressive growth.

Klook currently includes more than 1,200 activities across 24 destinations in Asia, that’s up from around 1,000 earlier this year. The company claims to have grown its userbase — which it counts as the total reach for its website, mobile apps, WeChat and other touch points — from 200,000 to 500,000 over the same period. It didn’t say how many bookings or customers it has, but that it “serves thousands of travelers a day.”

To offer activities at lower prices than traditional travel firms or tour operators, Klook works directly with attraction managers and owners. That way, it doesn’t involve agents or other aggregators who, once adding in their commission, push prices up for travelers.

Fah said that Greater China accounts for around one-third of its user base, with Southeast Asia also around the same figure. While Asia is a popular destination for tourists worldwide, Klook is particularly focused on unlocking the potential of Asian travelers.

“We’re a pan-Asia platform that serves both Asian destinations and Asian travelers,” he explained to TechCrunch in an interview. “The rising middle class in Asia make lots of inter-regional travel.”

This new funding will go towards growing the destinations and activities on the Klook platform, and further developing its technology. The company also plans to begin spending money on marketing, having relied on partnership deals and word-of-mouth for visibility thus far. Part of that focus will see it open an office in Singapore to increase its focus on Southeast Asia. Klook may also expand its physical presence into other local markets further down the line, Fah said.

The startup is also welcoming a pair of new strategy advisors who could help open doors. Wilfred Fan is managing director of Agoda and head of its business operations in North Asia, while Shuren Hu is a former vice chairman of the planning and financial department of the China National Tourism Administration.

If you’re wondering which cities are hot in Asia — Fah said Hong Kong is Klook’s top choice for visitors, followed by Singapore and Bangkok. You can see what they have on offer at Klook.com, or via its Android and iOS apps.

 


0
All topics: 7

Site search


Last comments

Walmart retreats from its UK Asda business to hone its focus on competing with Amazon
Peter Short
Good luck
Peter Short

Evolve Foundation launches a $100 million fund to find startups working to relieve human suffering
Peter Short
Money will give hope
Peter Short

Boeing will build DARPA’s XS-1 experimental spaceplane
Peter Short
Great
Peter Short

Is a “robot tax” really an “innovation penalty”?
Peter Short
It need to be taxed also any organic substance ie food than is used as a calorie transfer needs tax…
Peter Short

Twitter Is Testing A Dedicated GIF Button On Mobile
Peter Short
Sounds great Facebook got a button a few years ago
Then it disappeared Twitter needs a bottom maybe…
Peter Short

Apple’s Next iPhone Rumored To Debut On September 9th
Peter Short
Looks like a nice cycle of a round year;)
Peter Short

AncestryDNA And Google’s Calico Team Up To Study Genetic Longevity
Peter Short
I'm still fascinated by DNA though I favour pure chemistry what could be
Offered is for future gen…
Peter Short

U.K. Push For Better Broadband For Startups
Verg Matthews
There has to an email option icon to send to the clowns in MTNL ... the govt of India's service pro…
Verg Matthews

CrunchWeek: Apple Makes Music, Oculus Aims For Mainstream, Twitter CEO Shakeup
Peter Short
Noted Google maybe grooming Twitter as a partner in Social Media but with whistle blowing coming to…
Peter Short

CrunchWeek: Apple Makes Music, Oculus Aims For Mainstream, Twitter CEO Shakeup
Peter Short
Noted Google maybe grooming Twitter as a partner in Social Media but with whistle blowing coming to…
Peter Short